Two Sigma Advisers LP increased its position in shares of Abiomed (NASDAQ:ABMD) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,430 shares of the medical equipment provider’s stock after acquiring an additional 800 shares during the period. Two Sigma Advisers LP’s holdings in Abiomed were worth $2,142,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crow Point Partners LLC acquired a new stake in Abiomed in the 4th quarter valued at about $120,000. Cerebellum GP LLC purchased a new position in shares of Abiomed in the 4th quarter valued at about $127,000. SeaCrest Wealth Management LLC purchased a new position in Abiomed during the 4th quarter worth approximately $183,000. Advisor Partners LLC purchased a new position in Abiomed during the 4th quarter worth approximately $209,000. Finally, First Allied Advisory Services Inc. purchased a new position in Abiomed during the 3rd quarter worth approximately $234,000. 88.41% of the stock is currently owned by hedge funds and other institutional investors.
ABMD has been the topic of a number of research reports. Jefferies Group raised their price target on Abiomed to $250.00 and gave the stock a “buy” rating in a research note on Friday, January 12th. BidaskClub raised Abiomed from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Piper Jaffray reaffirmed a “buy” rating on shares of Abiomed in a report on Thursday, January 4th. Zacks Investment Research raised Abiomed from a “hold” rating to a “buy” rating and set a $213.00 price target for the company in a research report on Friday, December 29th. Finally, Guggenheim reissued a “buy” rating and set a $280.00 price target on shares of Abiomed in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $309.50.
NASDAQ:ABMD opened at $296.74 on Monday. Abiomed has a one year low of $117.36 and a one year high of $304.28. The stock has a market capitalization of $13,139.00, a P/E ratio of 154.55, a price-to-earnings-growth ratio of 2.91 and a beta of 0.16.
Abiomed (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.20. Abiomed had a return on equity of 15.54% and a net margin of 16.58%. The business had revenue of $154.00 million for the quarter, compared to analysts’ expectations of $154.00 million. During the same quarter in the previous year, the firm posted $0.34 earnings per share. The company’s revenue was up 34.9% compared to the same quarter last year. analysts forecast that Abiomed will post 2.29 EPS for the current year.
In other news, VP Andrew J. Greenfield sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total transaction of $5,407,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.00% of the company’s stock.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.